Discovery of a potential novel pharmacogenomic biomarker on ANK3 gene for liafensine, a triple reuptake inhibitor for treatment-resistant depression.

doi:10.1038/s41398-026-04144-w

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Discovery of a potential novel pharmacogenomic biomarker on ANK3 gene for liafensine, a triple reuptake inhibitor for treatment-resistant depression.

Translational psychiatry - 19 Jun 2026

Luo Wen, Wang Gang, Whitaker John W, Dhali Zafrin, Sun Hong, Lu Haiping, Li Xiaojun, Shi Tao, Zhang Jinkun

Abstract excerpt

Liafensine is a triple reuptake inhibitor targeting transporters for serotonin, norepinephrine, and dopamine for treatment-resistant depression (TRD). It did not exhibit efficacy in non-biomarker-selected TRD patients in two Phase 2b studies. We utilized the blood samples from the patients enrolled in these two studies and extracted genomic DNA to conduct a genome‑wide association study aiming to find a biomarker...

Topics

Join the communities discussing this publication.

Ankyrins
Biomarkers
ANK3 gene
TRD gene
Genetic Markers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Genome-Wide Association Study

Pharmacogenetics

Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 42321177
DOI: 10.1038/s41398-026-04144-w
PMCID: PMC13522506

Genes

ANK3
TRD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.